how does glp-1 agonist suppress appetite for Weight Loss and Diabetes Mechanisms of GLP-1 Receptor Agonist-Induced
Description
| 228 comments on LinkedIn

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma

Dosing in kidney and liver disease is also covered, along with drug interactions.

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase depression risk, a new review concludes.

Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.

These actions improve glycemic control and support weight loss
